Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q4 CY2024, with sales up 7.2% year on year to $10.97 ...

We recently published a list of Jim Cramer Breaks Silence On DeepSeek AI Sell-Off & Discusses These 12 Stocks. In this ...

A product made in Columbus reached a major milestone at the end of 2024. Ensure, a nutritional drink made by Abbott ...

This was the stock's fifth consecutive day of gains.

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Abbott Laboratories (NYSE: ABT) Q4 2024 Earnings Call Jan 22, 2025, 9:30 a.m. ET ...

The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 ...

Abbott Laboratories (ABT) reported weaker-than-expected fourth quarter sales due to weakness in its nutrition and diagnostics ...

Oppenheimer has recently initiated Abbott Laboratories (ABT) stock to Outperform rating, as announced on October 8, 2024, according to Finviz. Earlier, on September 19, 2024, Piper Sandler had ...

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street estimates, along with weak fourth-quarter ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

In a report released yesterday, David Toung from Argus Research maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The ...